Jae Park, MD from Memorial Sloan Kettering Cancer Center, New York, NY discusses current research in acute lymphoblastic leukemia (ALL). Dr Park first discusses a Phase III TOWER study which investigated blinatumomab vs standard of care (NCT02013167), with results showing blinatumomab performing better than conventional therapy. Then Dr Park continued to discuss a second trial on inotuzaumab, which also is compared to a standard of care arm. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
The sucess of Phase III TOWER study investigating ALL
